{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:34:31Z","timestamp":1794652471062,"version":"4.9.1"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003549","name":"Hungarian Scientific Research Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00005"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00005"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The prevalence of hypertriglyceridemia has been increasing worldwide. Attention is drawn to the fact that the frequency of a special hypertriglyceridemia entity, named chylomicronemia syndrome, is variable among its different forms. The monogenic form, termed familial chylomicronemia syndrome, is rare, occuring in 1 in every 1 million persons. On the other hand, the prevalence of the polygenic form of chylomicronemia syndrome is around 1:600. On the basis of the genetical alterations, other factors, such as obesity, alcohol consumption, uncontrolled diabetes mellitus and certain drugs may significantly contribute to the development of the multifactorial form. In this review, we aimed to highlight the recent findings about the clinical and laboratory features, differential diagnosis, as well as the epidemiology of the monogenic and polygenic forms of chylomicronemias. Regarding the therapy, differentiation between the two types of the chylomicronemia syndrome is essential, as well. Thus, proper treatment options of chylomicronemia and hypertriglyceridemia will be also summarized, emphasizing the newest therapeutic approaches, as novel agents may offer solution for the effective treatment of these conditions.<\/jats:p>","DOI":"10.1186\/s12944-022-01631-z","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T15:11:53Z","timestamp":1644505913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia"],"prefix":"10.1186","volume":"21","author":[{"given":"Gy\u00f6rgy","family":"Paragh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1kos","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariann","family":"Harangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"1631_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fendo.2020.00616","volume":"11","author":"LS Santos-Baez","year":"2020","unstructured":"Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front Endocrinol (Lausanne). 2020;11:616. https:\/\/doi.org\/10.3389\/fendo.2020.00616.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1631_CR2","doi-asserted-by":"publisher","first-page":"593931","DOI":"10.3389\/fendo.2020.593931","volume":"11","author":"RB Goldberg","year":"2020","unstructured":"Goldberg RB, Chait A. A Comprehensive Update on the Chylomicronemia Syndrome. Front Endocrinol (Lausanne). 2020;11:593931. https:\/\/doi.org\/10.3389\/fendo.2020.593931.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1631_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1503\/cmaj.060963","volume":"176","author":"G Yuan","year":"2007","unstructured":"Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113\u201320. https:\/\/doi.org\/10.1503\/cmaj.060963.","journal-title":"CMAJ."},{"issue":"12","key":"1631_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00109-002-0384-9","volume":"80","author":"JR Mead","year":"2002","unstructured":"Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002;80(12):753\u201369. https:\/\/doi.org\/10.1007\/s00109-002-0384-9.","journal-title":"J Mol Med (Berl)"},{"issue":"10","key":"1631_CR5","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1172\/JCI35206","volume":"118","author":"KJ Williams","year":"2008","unstructured":"Williams KJ. Molecular processes that handle -- and mishandle -- dietary lipids. J Clin Invest. 2008;118(10):3247\u201359. https:\/\/doi.org\/10.1172\/JCI35206.","journal-title":"J Clin Invest"},{"key":"1631_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cca.2014.08.022","volume":"438","author":"M Okubo","year":"2015","unstructured":"Okubo M, Toromanovic A, Ebara T, Murase T. Apolipoprotein C-II Tuzla: a novel large deletion in APOC2 caused by Alu-Alu homologous recombination in an infant with apolipoprotein C-II deficiency. Clin Chim Acta. 2015;438:148\u201353. https:\/\/doi.org\/10.1016\/j.cca.2014.08.022.","journal-title":"Clin Chim Acta"},{"issue":"1\u20132","key":"1631_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cca.2005.07.025","volume":"364","author":"CW Lam","year":"2006","unstructured":"Lam CW, Yuen YP, Cheng WF, Chan YW, Tong SF. Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta. 2006;364(1\u20132):256\u20139. https:\/\/doi.org\/10.1016\/j.cca.2005.07.025.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"1631_CR8","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0022-2275(20)37463-0","volume":"37","author":"R Streicher","year":"1996","unstructured":"Streicher R, Geisel J, Weisshaar C, Avci H, Oette K, M\u00fcller-Wieland D, et al. A single nucleotide substitution in the promoter region of the apolipoprotein C-II gene identified in individuals with chylomicronemia. J Lipid Res. 1996;37(12):2599\u2013607. https:\/\/doi.org\/10.1016\/S0022-2275(20)37463-0.","journal-title":"J Lipid Res"},{"issue":"5","key":"1631_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.bbalip.2011.10.006","volume":"1821","author":"M P\u00e9terfy","year":"2012","unstructured":"P\u00e9terfy M. Lipase maturation factor 1: a lipase chaperone involved in lipid metabolism. Biochim Biophys Acta. 2012;1821(5):790\u20134. https:\/\/doi.org\/10.1016\/j.bbalip.2011.10.006.","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"1631_CR10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1194\/jlr.R018689","volume":"52","author":"SG Young","year":"2011","unstructured":"Young SG, Davies BS, Voss CV, Gin P, Weinstein MM, Tontonoz P, et al. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res. 2011;52(11):1869\u201384. https:\/\/doi.org\/10.1194\/jlr.R018689.","journal-title":"J Lipid Res"},{"issue":"2","key":"1631_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/01.mol.0000217892.00618.54","volume":"17","author":"S Calandra","year":"2006","unstructured":"Calandra S, Priore Oliva C, Tarugi P, Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol. 2006;17(2):122\u20137. https:\/\/doi.org\/10.1097\/01.mol.0000217892.00618.54.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"1631_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","volume":"219","author":"SK Nilsson","year":"2011","unstructured":"Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis. 2011;219(1):15\u201321. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.07.019.","journal-title":"Atherosclerosis."},{"issue":"11","key":"1631_CR13","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1161\/CIRCRESAHA.113.301464","volume":"112","author":"MW Huff","year":"2013","unstructured":"Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res. 2013;112(11):1405\u20138. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.301464.","journal-title":"Circ Res"},{"issue":"12","key":"1631_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrendo.2017.119","volume":"13","author":"S Kersten","year":"2017","unstructured":"Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731\u20139. https:\/\/doi.org\/10.1038\/nrendo.2017.119.","journal-title":"Nat Rev Endocrinol"},{"issue":"43","key":"1631_CR15","doi-asserted-by":"publisher","first-page":"41804","DOI":"10.1074\/jbc.M302861200","volume":"278","author":"M Ono","year":"2003","unstructured":"Ono M, Shimizugawa T, Shimamura M, Yoshida K, Noji-Sakikawa C, Ando Y, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem. 2003;278(43):41804\u20139. https:\/\/doi.org\/10.1074\/jbc.M302861200.","journal-title":"J Biol Chem"},{"issue":"37","key":"1631_CR16","doi-asserted-by":"publisher","first-page":"33742","DOI":"10.1074\/jbc.M203215200","volume":"277","author":"T Shimizugawa","year":"2002","unstructured":"Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277(37):33742\u20138. https:\/\/doi.org\/10.1074\/jbc.M203215200.","journal-title":"J Biol Chem"},{"issue":"20","key":"1631_CR17","doi-asserted-by":"publisher","first-page":"13735","DOI":"10.1074\/jbc.M807899200","volume":"284","author":"EC Lee","year":"2009","unstructured":"Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem. 2009;284(20):13735\u201345. https:\/\/doi.org\/10.1074\/jbc.M807899200.","journal-title":"J Biol Chem"},{"issue":"3","key":"1631_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1074\/jbc.M808477200","volume":"284","author":"L Shan","year":"2009","unstructured":"Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284(3):1419\u201324. https:\/\/doi.org\/10.1074\/jbc.M808477200.","journal-title":"J Biol Chem"},{"issue":"12","key":"1631_CR19","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1194\/jlr.M900145-JLR200","volume":"50","author":"WK Sonnenburg","year":"2009","unstructured":"Sonnenburg WK, Yu D, Lee EC, Xiong W, Gololobov G, Key B, et al. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J Lipid Res. 2009;50(12):2421\u20139. https:\/\/doi.org\/10.1194\/jlr.M900145-JLR200.","journal-title":"J Lipid Res"},{"issue":"18","key":"1631_CR20","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1074\/jbc.M809802200","volume":"284","author":"MH Yau","year":"2009","unstructured":"Yau MH, Wang Y, Lam KS, Zhang J, Wu D, Xu A. A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem. 2009;284(18):11942\u201352. https:\/\/doi.org\/10.1074\/jbc.M809802200.","journal-title":"J Biol Chem"},{"issue":"48","key":"1631_CR21","doi-asserted-by":"publisher","first-page":"19751","DOI":"10.1073\/pnas.1217552109","volume":"109","author":"F Quagliarini","year":"2012","unstructured":"Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012;109(48):19751\u20136. https:\/\/doi.org\/10.1073\/pnas.1217552109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1631_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.molmet.2017.06.014","volume":"6","author":"X Chi","year":"2017","unstructured":"Chi X, Britt EC, Shows HW, Hjelmaas AJ, Shetty SK, Cushing EM, et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab. 2017;6(10):1137\u201349. https:\/\/doi.org\/10.1016\/j.molmet.2017.06.014.","journal-title":"Mol Metab"},{"issue":"5","key":"1631_CR23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","volume":"1821","author":"F Mattijssen","year":"2012","unstructured":"Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta. 2012;1821(5):782\u20139. https:\/\/doi.org\/10.1016\/j.bbalip.2011.10.010.","journal-title":"Biochim Biophys Acta"},{"key":"1631_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","volume":"267","author":"A Wolska","year":"2017","unstructured":"Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, et al. Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis. 2017;267:49\u201360. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.10.025.","journal-title":"Atherosclerosis."},{"issue":"3","key":"1631_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacl.2014.02.006","volume":"8","author":"N Chokshi","year":"2014","unstructured":"Chokshi N, Blumenschein SD, Ahmad Z, Garg A. Genotype-phenotype relationships in patients with type I hyperlipoproteinemia. J Clin Lipidol. 2014;8(3):287\u201395. https:\/\/doi.org\/10.1016\/j.jacl.2014.02.006.","journal-title":"J Clin Lipidol."},{"issue":"1\u20132","key":"1631_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11010-008-0005-1","volume":"326","author":"RA Hegele","year":"2009","unstructured":"Hegele RA, Pollex RL. Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem. 2009;326(1\u20132):35\u201343. https:\/\/doi.org\/10.1007\/s11010-008-0005-1.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"1631_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrg2481","volume":"10","author":"RA Hegele","year":"2009","unstructured":"Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10(2):109\u201321. https:\/\/doi.org\/10.1038\/nrg2481.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"1631_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.R009720","volume":"52","author":"CT Johansen","year":"2011","unstructured":"Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189\u2013206. https:\/\/doi.org\/10.1194\/jlr.R009720.","journal-title":"J Lipid Res"},{"issue":"1","key":"1631_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5551\/jat.10702","volume":"19","author":"T Gotoda","year":"2012","unstructured":"Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, et al. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19(1):1\u201312. https:\/\/doi.org\/10.5551\/jat.10702.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"1631_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjmed.2007.10.004","volume":"121","author":"DA Leaf","year":"2008","unstructured":"Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008;121(1):10\u20132. https:\/\/doi.org\/10.1016\/j.amjmed.2007.10.004.","journal-title":"Am J Med"},{"issue":"7","key":"1631_CR31","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1161\/01.atv.17.7.1400","volume":"17","author":"M Rouis","year":"1997","unstructured":"Rouis M, Dugi KA, Previato L, Patterson AP, Brunzell JD, Brewer HB, et al. Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome. Arterioscler Thromb Vasc Biol. 1997;17(7):1400\u20136. https:\/\/doi.org\/10.1161\/01.atv.17.7.1400.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1631_CR32","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1172\/JCI106436","volume":"49","author":"F Parker","year":"1970","unstructured":"Parker F, Bagdade JD, Odland GF, Bierman EL. Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: a correlative lipid biochemical, histochemical, and electron microscopic study. J Clin Invest. 1970;49(12):2172\u201387. https:\/\/doi.org\/10.1172\/JCI106436.","journal-title":"J Clin Invest"},{"issue":"20","key":"1631_CR33","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1056\/NEJMcp054958","volume":"354","author":"DC Whitcomb","year":"2006","unstructured":"Whitcomb DC. Clinical practice. Acute pancreatitis N Engl J Med. 2006;354(20):2142\u201350. https:\/\/doi.org\/10.1056\/NEJMcp054958.","journal-title":"Acute pancreatitis N Engl J Med"},{"issue":"8","key":"1631_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","volume":"25","author":"P Valdivielso","year":"2014","unstructured":"Valdivielso P, Ram\u00edrez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2014.08.008.","journal-title":"Eur J Intern Med"},{"issue":"9","key":"1631_CR35","first-page":"633","volume":"77","author":"JH Ranson","year":"1982","unstructured":"Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. Am J Gastroenterol. 1982;77(9):633\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1631_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1148\/radiology.174.2.2296641","volume":"174","author":"EJ Balthazar","year":"1990","unstructured":"Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology. 1990;174(2):331\u20136. https:\/\/doi.org\/10.1148\/radiology.174.2.2296641.","journal-title":"Radiology."},{"issue":"12","key":"1631_CR37","first-page":"2134","volume":"90","author":"MR Fortson","year":"1995","unstructured":"Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1631_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1476-511X-10-157","volume":"10","author":"S Sandhu","year":"2011","unstructured":"Sandhu S, Al-Sarraf A, Taraboanta C, Frohlich J, Francis GA. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis. 2011;10(1):157. https:\/\/doi.org\/10.1186\/1476-511X-10-157.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"1631_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2012.08.007","volume":"6","author":"JB Christian","year":"2012","unstructured":"Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6(5):450\u201361. https:\/\/doi.org\/10.1016\/j.jacl.2012.08.007.","journal-title":"J Clin Lipidol."},{"issue":"3","key":"1631_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/s0022-3476(98)70280-x","volume":"133","author":"JC Feoli-Fonseca","year":"1998","unstructured":"Feoli-Fonseca JC, L\u00e9vy E, Godard M, Lambert M. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J Pediatr. 1998;133(3):417\u201323. https:\/\/doi.org\/10.1016\/s0022-3476(98)70280-x.","journal-title":"J Pediatr"},{"issue":"1","key":"1631_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/011542650401900105","volume":"19","author":"AS Khokhar","year":"2004","unstructured":"Khokhar AS, Seidner DL. The pathophysiology of pancreatitis. Nutr Clin Pract. 2004;19(1):5\u201315. https:\/\/doi.org\/10.1177\/011542650401900105.","journal-title":"Nutr Clin Pract"},{"issue":"3","key":"1631_CR42","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/nu5030981","volume":"5","author":"A Brahm","year":"2013","unstructured":"Brahm A, Hegele RA. Hypertriglyceridemia. Hypertriglyceridemia Nutrients. 2013;5(3):981\u20131001. https:\/\/doi.org\/10.3390\/nu5030981.","journal-title":"Hypertriglyceridemia Nutrients"},{"issue":"8","key":"1631_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","volume":"2","author":"RA Hegele","year":"2014","unstructured":"Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2(8):655\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(13)70191-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1631_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ymgme.2007.10.007","volume":"93","author":"AR Rahalkar","year":"2008","unstructured":"Rahalkar AR, Hegele RA. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab. 2008;93(3):282\u201394. https:\/\/doi.org\/10.1016\/j.ymgme.2007.10.007.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1631_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1525-1470.2007.00415.x","volume":"24","author":"S Sugandhan","year":"2007","unstructured":"Sugandhan S, Khandpur S, Sharma VK. Familial chylomicronemia syndrome. Pediatr Dermatol. 2007;24(3):323\u20135. https:\/\/doi.org\/10.1111\/j.1525-1470.2007.00415.x.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1631_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/s0025-7125(16)31430-4","volume":"66","author":"JD Brunzell","year":"1982","unstructured":"Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am. 1982;66(2):455\u201368. https:\/\/doi.org\/10.1016\/s0025-7125(16)31430-4.","journal-title":"Med Clin North Am"},{"issue":"6","key":"1631_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2015.26","volume":"11","author":"AJ Brahm","year":"2015","unstructured":"Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11(6):352\u201362. https:\/\/doi.org\/10.1038\/nrendo.2015.26.","journal-title":"Nat Rev Endocrinol."},{"key":"1631_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cca.2013.11.025","volume":"429","author":"JM Mart\u00edn-Campos","year":"2014","unstructured":"Mart\u00edn-Campos JM, Julve J, Roig R, Mart\u00ednez S, Errico TL, Mart\u00ednez-Couselo S, et al. Molecular analysis of chylomicronemia in a clinical laboratory setting: diagnosis of 13 cases of lipoprotein lipase deficiency. Clin Chim Acta. 2014;429:61\u20138. https:\/\/doi.org\/10.1016\/j.cca.2013.11.025.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1631_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.atherosclerosissup.2012.10.020","volume":"14","author":"C Stefanutti","year":"2013","unstructured":"Stefanutti C, Gozzer M, Pisciotta L, D'Eufemia P, Bosco G, Morozzi C, et al. A three month-old infant with severe hyperchylomicronemia: molecular diagnosis and extracorporeal treatment. Atheroscler Suppl. 2013;14(1):73\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.020.","journal-title":"Atheroscler Suppl."},{"issue":"19","key":"1631_CR50","doi-asserted-by":"publisher","first-page":"7980","DOI":"10.1073\/pnas.1100992108","volume":"108","author":"CV Voss","year":"2011","unstructured":"Voss CV, Davies BS, Tat S, Gin P, Fong LG, Pelletier C, et al. Mutations in lipoprotein lipase that block binding to the endothelial cell transporter GPIHBP1. Proc Natl Acad Sci U S A. 2011;108(19):7980\u20134. https:\/\/doi.org\/10.1073\/pnas.1100992108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"1631_CR51","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cccn.2004.01.029","volume":"343","author":"D Pasali\u0107","year":"2004","unstructured":"Pasali\u0107 D, Jurci\u0107 Z, Stipanci\u0107 G, Ferencak G, Leren TP, Djurovic S, et al. Missense mutation W86R in exon 3 of the lipoprotein lipase gene in a boy with chylomicronemia. Clin Chim Acta. 2004;343(1\u20132):179\u201384. https:\/\/doi.org\/10.1016\/j.cccn.2004.01.029.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1631_CR52","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00006676-200308000-00003","volume":"27","author":"TS Jap","year":"2003","unstructured":"Jap TS, Jenq SF, Wu YC, Chiu CY, Cheng HM. Mutations in the lipoprotein lipase gene as a cause of hypertriglyceridemia and pancreatitis in Taiwan. Pancreas. 2003;27(2):122\u20136. https:\/\/doi.org\/10.1097\/00006676-200308000-00003.","journal-title":"Pancreas."},{"issue":"4","key":"1631_CR53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(sici)1096-8628(19980724)78:4<313::aid-ajmg1>3.0.co;2-m","volume":"78","author":"HE Henderson","year":"1998","unstructured":"Henderson HE, Bijvoet SM, Mannens MA, Bruin T, Erkelens DW, Hayden MR, et al. Ile225Thr loop mutation in the lipoprotein lipase (LPL) gene is a de novo event. Am J Med Genet. 1998;78(4):313\u20136. https:\/\/doi.org\/10.1002\/(sici)1096-8628(19980724)78:4<313::aid-ajmg1>3.0.co;2-m.","journal-title":"Am J Med Genet"},{"key":"1631_CR54","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1002\/humu.1380110148","volume":"Suppl 1","author":"L Foubert","year":"1998","unstructured":"Foubert L, De Gennes JL, Benlian P, Truffert J, Miao L, Hayden MR. Compound heterozygosity for frameshift mutations in the gene for lipoprotein lipase in a patient with early-onset chylomicronemia. Hum Mutat. 1998;Suppl 1:S141\u20134. https:\/\/doi.org\/10.1002\/humu.1380110148.","journal-title":"Hum Mutat"},{"issue":"3","key":"1631_CR55","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0888-7543(92)90136-g","volume":"13","author":"Y Ma","year":"1992","unstructured":"Ma Y, Wilson BI, Bijvoet S, Henderson HE, Cramb E, Roederer G, et al. A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics. 1992;13(3):649\u201353. https:\/\/doi.org\/10.1016\/0888-7543(92)90136-g.","journal-title":"Genomics."},{"issue":"21","key":"1631_CR56","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1093\/hmg\/ddp361","volume":"18","author":"RA Hegele","year":"2009","unstructured":"Hegele RA, Ban MR, Hsueh N, Kennedy BA, Cao H, Zou GY, et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet. 2009;18(21):4189\u201394. https:\/\/doi.org\/10.1093\/hmg\/ddp361.","journal-title":"Hum Mol Genet"},{"key":"1631_CR57","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fendo.2020.00455","volume":"11","author":"JS Dron","year":"2020","unstructured":"Dron JS, Hegele RA. Genetics of Hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455. https:\/\/doi.org\/10.3389\/fendo.2020.00455.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1631_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2013.12.009","volume":"233","author":"K Albers","year":"2014","unstructured":"Albers K, Schlein C, Wenner K, Lohse P, Bartelt A, Heeren J, et al. Homozygosity for a partial deletion of apoprotein A-V signal peptide results in intracellular missorting of the protein and chylomicronemia in a breast-fed infant. Atherosclerosis. 2014;233(1):97\u2013103. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.009.","journal-title":"Atherosclerosis."},{"issue":"6","key":"1631_CR59","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jacl.2018.07.013","volume":"12","author":"MJ Ariza","year":"2018","unstructured":"Ariza MJ, Rioja J, Ibarretxe D, Camacho A, D\u00edaz-D\u00edaz JL, Mangas A, et al. Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. J Clin Lipidol. 2018;12(6):1482\u201392.e3. https:\/\/doi.org\/10.1016\/j.jacl.2018.07.013.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"1631_CR60","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1185\/03007995.2014.909394","volume":"30","author":"A Pirillo","year":"2014","unstructured":"Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30(8):1489\u2013503. https:\/\/doi.org\/10.1185\/03007995.2014.909394.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1631_CR61","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1210\/clinem\/dgaa838","volume":"106","author":"M Belhassen","year":"2021","unstructured":"Belhassen M, Van Ganse E, Nolin M, B\u00e9rard M, Bada H, Bruckert E, et al. 10-year comparative follow-up of familial versus multifactorial Chylomicronemia syndromes. J Clin Endocrinol Metab. 2021;106(3):e1332\u2013e42. https:\/\/doi.org\/10.1210\/clinem\/dgaa838.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1631_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1210\/er.2014-1062","volume":"36","author":"GF Lewis","year":"2015","unstructured":"Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36(1):131\u201347. https:\/\/doi.org\/10.1210\/er.2014-1062.","journal-title":"Endocr Rev"},{"issue":"9","key":"1631_CR63","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7326\/M19-0203","volume":"170","author":"A Chait","year":"2019","unstructured":"Chait A, Eckel RH. The Chylomicronemia syndrome is Most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170(9):626\u201334. https:\/\/doi.org\/10.7326\/M19-0203.","journal-title":"Ann Intern Med"},{"key":"1631_CR64","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/DMSO.S206053","volume":"13","author":"C Bagias","year":"2020","unstructured":"Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial partial lipodystrophy (FPLD): recent insights. Diabetes Metab Syndr Obes. 2020;13:1531\u201344. https:\/\/doi.org\/10.2147\/DMSO.S206053.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1631_CR65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.3714","volume":"49","author":"LA Lotta","year":"2017","unstructured":"Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17\u201326. https:\/\/doi.org\/10.1038\/ng.3714.","journal-title":"Nat Genet"},{"issue":"2","key":"1631_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1471-0528.1978.tb10466.x","volume":"85","author":"DP Muller","year":"1978","unstructured":"Muller DP, Pavlou C, Whitelaw AG, McLintock D. The effect of pregnancy and two different contraceptive pills on serum lipids and lipoproteins in a woman with a type III hyperlipoproteinaemia pattern. Br J Obstet Gynaecol. 1978;85(2):127\u201333. https:\/\/doi.org\/10.1111\/j.1471-0528.1978.tb10466.x.","journal-title":"Br J Obstet Gynaecol"},{"issue":"17","key":"1631_CR67","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1611930","volume":"376","author":"AP Beigneux","year":"2017","unstructured":"Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, et al. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med. 2017;376(17):1647\u201358. https:\/\/doi.org\/10.1056\/NEJMoa1611930.","journal-title":"N Engl J Med"},{"issue":"2","key":"1631_CR68","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1001\/2013.jamainternmed.477","volume":"173","author":"MJ Murphy","year":"2013","unstructured":"Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173(2):162\u20134. https:\/\/doi.org\/10.1001\/2013.jamainternmed.477.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"1631_CR69","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","volume":"176","author":"SB Pedersen","year":"2016","unstructured":"Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176(12):1834\u201342. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6875.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"1631_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/1744-9987.12008","volume":"17","author":"C Stefanutti","year":"2013","unstructured":"Stefanutti C, Labbadia G, Morozzi C. Severe hypertriglyceridemia-related acute pancreatitis. Ther Apher Dial. 2013;17(2):130\u20137. https:\/\/doi.org\/10.1111\/1744-9987.12008.","journal-title":"Ther Apher Dial"},{"issue":"5","key":"1631_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14779072.2017.1311786","volume":"15","author":"M Davidson","year":"2017","unstructured":"Davidson M, Stevenson M, Hsieh A, Ahmad Z, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. Expert Rev Cardiovasc Ther. 2017;15(5):415\u201323. https:\/\/doi.org\/10.1080\/14779072.2017.1311786.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"11","key":"1631_CR72","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14779072.2017.1372193","volume":"15","author":"A Gelrud","year":"2017","unstructured":"Gelrud A, Williams KR, Hsieh A, Gwosdow AR, Gilstrap A, Brown A. The burden of familial chylomicronemia syndrome from the patients' perspective. Expert Rev Cardiovasc Ther. 2017;15(11):879\u201387. https:\/\/doi.org\/10.1080\/14779072.2017.1372193.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1631_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2017.07.030","volume":"265","author":"O Marmontel","year":"2017","unstructured":"Marmontel O, Di Filippo M, Marcais C, Nony S, Dumoux M, Serveaux-Dancer M, et al. Alterations in plasma triglycerides lipolysis in patients with history of multifactorial chylomicronemia. Atherosclerosis. 2017;265:22\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.07.030.","journal-title":"Atherosclerosis."},{"key":"1631_CR74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","volume":"275","author":"P Moulin","year":"2018","unstructured":"Moulin P, Dufour R, Averna M, Arca M, Cefal\u00f9 AB, Noto D, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\". Atherosclerosis. 2018;275:265\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.814.","journal-title":"Atherosclerosis."},{"issue":"4","key":"1631_CR75","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11892-010-0124-4","volume":"10","author":"I Jialal","year":"2010","unstructured":"Jialal I, Amess W, Kaur M. Management of hypertriglyceridemia in the diabetic patient. Curr Diab Rep. 2010;10(4):316\u201320. https:\/\/doi.org\/10.1007\/s11892-010-0124-4.","journal-title":"Curr Diab Rep"},{"issue":"22","key":"1631_CR76","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1001\/jama.1989.03430220077034","volume":"262","author":"DA Leaf","year":"1989","unstructured":"Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G. the hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study. JAMA. 1989;262(22):3154\u201360. https:\/\/doi.org\/10.1001\/jama.1989.03430220077034.","journal-title":"JAMA."},{"issue":"10","key":"1631_CR77","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","volume":"10","author":"AM Gotto","year":"2013","unstructured":"Gotto AM, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol. 2013;10(10):560\u201370. https:\/\/doi.org\/10.1038\/nrcardio.2013.117.","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"1631_CR78","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.cir.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088\u201393. https:\/\/doi.org\/10.1161\/01.cir.98.19.2088.","journal-title":"Circulation."},{"key":"1631_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","volume":"56","author":"A Sahebkar","year":"2014","unstructured":"Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014;56:47\u201366. https:\/\/doi.org\/10.1016\/j.plipres.2014.07.002.","journal-title":"Prog Lipid Res"},{"issue":"1","key":"1631_CR80","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s12933-020-01172-8","volume":"19","author":"C Iitake","year":"2020","unstructured":"Iitake C, Masuda D, Koseki M, Yamashita S. Marked effects of novel selective peroxisome proliferator-activated receptor \u03b1 modulator, pemafibrate in severe hypertriglyceridemia: preliminary report. Cardiovasc Diabetol. 2020;19(1):201. https:\/\/doi.org\/10.1186\/s12933-020-01172-8.","journal-title":"Cardiovasc Diabetol"},{"key":"1631_CR81","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.cca.2020.07.031","volume":"510","author":"T Minamizuka","year":"2020","unstructured":"Minamizuka T, Kobayashi J, Tada H, Miyashita K, Koshizaka M, Maezawa Y, et al. Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency - effects of pemafibrate treatment. Clin Chim Acta. 2020;510:216\u20139. https:\/\/doi.org\/10.1016\/j.cca.2020.07.031.","journal-title":"Clin Chim Acta"},{"key":"1631_CR82","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.0954-6820.1963.tb17457.x","volume":"173","author":"LA CARLSON","year":"1963","unstructured":"CARLSON LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand. 1963;173:719\u201322. https:\/\/doi.org\/10.1111\/j.0954-6820.1963.tb17457.x.","journal-title":"Acta Med Scand"},{"issue":"8A","key":"1631_CR83","doi-asserted-by":"publisher","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","volume":"101","author":"VS Kamanna","year":"2008","unstructured":"Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B\u20136B. https:\/\/doi.org\/10.1016\/j.amjcard.2008.02.029.","journal-title":"Am J Cardiol"},{"issue":"9","key":"1631_CR84","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/s0002-9149(00)00703-7","volume":"85","author":"A Goldberg","year":"2000","unstructured":"Goldberg A, Alagona P, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9):1100\u20135. https:\/\/doi.org\/10.1016\/s0002-9149(00)00703-7.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1631_CR85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","volume":"48","author":"A Gille","year":"2008","unstructured":"Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48(1):79\u2013106. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094746.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"1631_CR86","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","volume":"44","author":"Y Park","year":"2003","unstructured":"Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44(3):455\u201363. https:\/\/doi.org\/10.1194\/jlr.M200282-JLR200.","journal-title":"J Lipid Res"},{"issue":"4A","key":"1631_CR87","doi-asserted-by":"publisher","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","volume":"98","author":"MH Davidson","year":"2006","unstructured":"Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i\u201333i. https:\/\/doi.org\/10.1016\/j.amjcard.2005.12.024.","journal-title":"Am J Cardiol"},{"issue":"7","key":"1631_CR88","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1517\/14656566.9.7.1237","volume":"9","author":"AC Skulas-Ray","year":"2008","unstructured":"Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008;9(7):1237\u201348. https:\/\/doi.org\/10.1517\/14656566.9.7.1237.","journal-title":"Expert Opin Pharmacother"},{"issue":"1 Dietary Lipid","key":"1631_CR89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-6632.1993.tb35689.x","volume":"683","author":"WE Connor","year":"1993","unstructured":"Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann N Y Acad Sci. 1993;683(1 Dietary Lipid):16\u201334. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb35689.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1631_CR90","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.beem.2013.10.002","volume":"28","author":"L Berglund","year":"2014","unstructured":"Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab. 2014;28(3):423\u201337. https:\/\/doi.org\/10.1016\/j.beem.2013.10.002.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1631_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1743-7075-9-9","volume":"9","author":"KM Slivkoff-Clark","year":"2012","unstructured":"Slivkoff-Clark KM, James AP, Mamo JC. The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men. Nutr Metab (Lond). 2012;9:9. https:\/\/doi.org\/10.1186\/1743-7075-9-9.","journal-title":"Nutr Metab (Lond)"},{"issue":"9","key":"1631_CR92","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1089\/jwh.2017.6757","volume":"27","author":"EA Brinton","year":"2018","unstructured":"Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT, Juliano RA, et al. Lipid effects of Icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis. J Women's Health (Larchmt). 2018;27(9):1170\u20136. https:\/\/doi.org\/10.1089\/jwh.2017.6757.","journal-title":"J Women's Health (Larchmt)"},{"issue":"1","key":"1631_CR93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"3","key":"1631_CR94","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1742-1241.2011.02867.x","volume":"66","author":"AS Wierzbicki","year":"2012","unstructured":"Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract. 2012;66(3):270\u201380. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02867.x.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"1631_CR95","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/cmdc.201402069","volume":"9","author":"R Naik","year":"2014","unstructured":"Naik R, Obiang-Obounou BW, Kim M, Choi Y, Lee HS, Lee K. Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltransferase (DGAT) inhibitors. ChemMedChem. 2014;9(11):2410\u201324. https:\/\/doi.org\/10.1002\/cmdc.201402069.","journal-title":"ChemMedChem."},{"issue":"24","key":"1631_CR96","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1021\/jm4007033","volume":"56","author":"RJ DeVita","year":"2013","unstructured":"DeVita RJ, Pinto S. Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. J Med Chem. 2013;56(24):9820\u20135. https:\/\/doi.org\/10.1021\/jm4007033.","journal-title":"J Med Chem"},{"issue":"2","key":"1631_CR97","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/dom.12002","volume":"15","author":"H Denison","year":"2013","unstructured":"Denison H, Nilsson C, Kujacic M, L\u00f6fgren L, Karlsson C, Knutsson M, et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes Metab. 2013;15(2):136\u201343. https:\/\/doi.org\/10.1111\/dom.12002.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1631_CR98","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/dom.12221","volume":"16","author":"H Denison","year":"2014","unstructured":"Denison H, Nilsson C, L\u00f6fgren L, Himmelmann A, M\u00e5rtensson G, Knutsson M, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014;16(4):334\u201343. https:\/\/doi.org\/10.1111\/dom.12221.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1631_CR99","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","volume":"23","author":"SA Khetarpal","year":"2017","unstructured":"Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017;23(9):1086\u201394. https:\/\/doi.org\/10.1038\/nm.4390.","journal-title":"Nat Med"},{"issue":"1","key":"1631_CR100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1538\/expanim.55.27","volume":"55","author":"K Fujimoto","year":"2006","unstructured":"Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim. 2006;55(1):27\u201334. https:\/\/doi.org\/10.1538\/expanim.55.27.","journal-title":"Exp Anim"},{"issue":"5","key":"1631_CR101","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacl.2012.04.003","volume":"6","author":"KC Maki","year":"2012","unstructured":"Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol. 2012;6(5):413\u201326. https:\/\/doi.org\/10.1016\/j.jacl.2012.04.003.","journal-title":"J Clin Lipidol."},{"issue":"11","key":"1631_CR102","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479\u201390. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.300367.","journal-title":"Circ Res"},{"issue":"1","key":"1631_CR103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-015-0006-5","volume":"14","author":"CD Meyers","year":"2015","unstructured":"Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015;14(1):8. https:\/\/doi.org\/10.1186\/s12944-015-0006-5.","journal-title":"Lipids Health Dis"},{"key":"1631_CR104","doi-asserted-by":"crossref","unstructured":"Pecin I, Nedic, M., Reiner, Z. Volanesorsen. Antisense oligonucleotide targeting ApoC-III, treatment of familial chylomicronemia syndrome, treatment of hypertriglyceridemia, treatment of lipodystrophy. Drugs Fut. 2016:417\u2013421.","DOI":"10.1358\/dof.2016.041.07.2485368"},{"issue":"6","key":"1631_CR105","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial Chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"1631_CR106","doi-asserted-by":"crossref","unstructured":"Ioanna Gouni-Berthold VA, Andres Digenio, Robert DuFour ES-T, Steve Martin, Patrick Moriarty, Steve Hughes JW, Daniel Gaudet, Eric Stroes. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. J Clin Lipidol. 2017:794\u20135.","DOI":"10.1016\/j.jacl.2017.04.038"},{"issue":"12","key":"1631_CR107","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","volume":"79","author":"J Paik","year":"2019","unstructured":"Paik J, Duggan S. Volanesorsen: First Global Approval. Drugs. 2019;79(12):1349\u201354. https:\/\/doi.org\/10.1007\/s40265-019-01168-z.","journal-title":"Drugs."},{"issue":"4","key":"1631_CR108","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, M\u00e9thot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310\u201320. https:\/\/doi.org\/10.1097\/MOL.0b013e3283555a7e.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"1631_CR109","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier AC, Frisch F, Labb\u00e9 SM, Gagnon R, de Wal J, Greentree S, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635\u201344. https:\/\/doi.org\/10.1210\/jc.2011-3002.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1631_CR110","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","volume":"20","author":"D Gaudet","year":"2013","unstructured":"Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361\u20139. https:\/\/doi.org\/10.1038\/gt.2012.43.","journal-title":"Gene Ther"},{"issue":"10","key":"1631_CR111","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbalip.2006.08.008","volume":"1761","author":"J Rip","year":"2006","unstructured":"Rip J, van Dijk KW, Sierts JA, Kastelein JJ, Twisk J, Kuivenhoven JA. AAV1-LPL(S447X) gene therapy reduces hypertriglyceridemia in apoE2 knock in mice. Biochim Biophys Acta. 2006;1761(10):1163\u20138. https:\/\/doi.org\/10.1016\/j.bbalip.2006.08.008.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"1631_CR112","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1194\/jlr.M075689","volume":"58","author":"JF Haller","year":"2017","unstructured":"Haller JF, Mintah IJ, Shihanian LM, Stevis P, Buckler D, Alexa-Braun CA, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017;58(6):1166\u201373. https:\/\/doi.org\/10.1194\/jlr.M075689.","journal-title":"J Lipid Res"},{"issue":"1","key":"1631_CR113","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1194\/jlr.m200367-jlr200","volume":"44","author":"R Kaplan","year":"2003","unstructured":"Kaplan R, Zhang T, Hernandez M, Gan FX, Wright SD, Waters MG, et al. Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res. 2003;44(1):136\u201343. https:\/\/doi.org\/10.1194\/jlr.m200367-jlr200.","journal-title":"J Lipid Res"},{"issue":"7","key":"1631_CR114","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1194\/jlr.M500005-JLR200","volume":"46","author":"H Ge","year":"2005","unstructured":"Ge H, Cha JY, Gopal H, Harp C, Yu X, Repa JJ, et al. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J Lipid Res. 2005;46(7):1484\u201390. https:\/\/doi.org\/10.1194\/jlr.M500005-JLR200.","journal-title":"J Lipid Res"},{"issue":"24","key":"1631_CR115","doi-asserted-by":"publisher","first-page":"21344","DOI":"10.1074\/jbc.M213202200","volume":"278","author":"T Inaba","year":"2003","unstructured":"Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, et al. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem. 2003;278(24):21344\u201351. https:\/\/doi.org\/10.1074\/jbc.M213202200.","journal-title":"J Biol Chem"},{"issue":"17","key":"1631_CR116","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1074\/jbc.M512554200","volume":"281","author":"C Fugier","year":"2006","unstructured":"Fugier C, Tousaint JJ, Prieur X, Plateroti M, Samarut J, Delerive P. The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone. J Biol Chem. 2006;281(17):11553\u20139. https:\/\/doi.org\/10.1074\/jbc.M512554200.","journal-title":"J Biol Chem"},{"issue":"4","key":"1631_CR117","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.bbrc.2004.03.151","volume":"317","author":"K Inukai","year":"2004","unstructured":"Inukai K, Nakashima Y, Watanabe M, Kurihara S, Awata T, Katagiri H, et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317(4):1075\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2004.03.151.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1631_CR118","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.bbrc.2009.12.145","volume":"391","author":"B Lu","year":"2010","unstructured":"Lu B, Moser A, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response stimulates the expression of angiopoietin like protein 4. Biochem Biophys Res Commun. 2010;391(4):1737\u201341. https:\/\/doi.org\/10.1016\/j.bbrc.2009.12.145.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20132","key":"1631_CR119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mce.2006.05.005","volume":"256","author":"K Matsusue","year":"2006","unstructured":"Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ. Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. Mol Cell Endocrinol. 2006;256(1\u20132):23\u201333. https:\/\/doi.org\/10.1016\/j.mce.2006.05.005.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"1631_CR120","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/s0006-291x(02)03058-9","volume":"301","author":"M Shimamura","year":"2003","unstructured":"Shimamura M, Matsuda M, Kobayashi S, Ando Y, Ono M, Koishi R, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun. 2003;301(2):604\u20139. https:\/\/doi.org\/10.1016\/s0006-291x(02)03058-9.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1631_CR121","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2796.2010.02305.x","volume":"269","author":"C Pramfalk","year":"2011","unstructured":"Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011;269(3):333\u20139. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02305.x.","journal-title":"J Intern Med"},{"issue":"2","key":"1631_CR122","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ng814","volume":"30","author":"R Koishi","year":"2002","unstructured":"Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002;30(2):151\u20137. https:\/\/doi.org\/10.1038\/ng814.","journal-title":"Nat Genet"},{"issue":"6","key":"1631_CR123","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jhep.2013.05.045","volume":"59","author":"A Sehgal","year":"2013","unstructured":"Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J Hepatol. 2013;59(6):1354\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2013.05.045.","journal-title":"J Hepatol"},{"issue":"7","key":"1631_CR124","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56(7):1308\u201317. https:\/\/doi.org\/10.1194\/jlr.M054890.","journal-title":"J Lipid Res"},{"issue":"7","key":"1631_CR125","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296\u2013307. https:\/\/doi.org\/10.1194\/jlr.M054882.","journal-title":"J Lipid Res"},{"issue":"6","key":"1631_CR126","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","volume":"44","author":"Y Ando","year":"2003","unstructured":"Ando Y, Shimizugawa T, Takeshita S, Ono M, Shimamura M, Koishi R, et al. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice. J Lipid Res. 2003;44(6):1216\u201323. https:\/\/doi.org\/10.1194\/jlr.M300031-JLR200.","journal-title":"J Lipid Res"},{"issue":"40","key":"1631_CR127","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41(40):3936\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa689.","journal-title":"Eur Heart J"},{"issue":"5","key":"1631_CR128","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S0022-2275(20)30112-7","volume":"43","author":"DC Chan","year":"2002","unstructured":"Chan DC, Watts GF, Barrett PH, Martins IJ, James AP, Mamo JC, et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res. 2002;43(5):706\u201312. https:\/\/doi.org\/10.1016\/S0022-2275(20)30112-7.","journal-title":"J Lipid Res"},{"issue":"9","key":"1631_CR129","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/phar.1441","volume":"34","author":"JA Marbach","year":"2014","unstructured":"Marbach JA, McKeon JL, Ross JL, Duffy D. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work. Pharmacotherapy. 2014;34(9):961\u201372. https:\/\/doi.org\/10.1002\/phar.1441.","journal-title":"Pharmacotherapy."},{"issue":"3","key":"1631_CR130","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","volume":"174","author":"FM Sacks","year":"2014","unstructured":"Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA Intern Med. 2014;174(3):443\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2013.13309.","journal-title":"JAMA Intern Med"},{"issue":"9860","key":"1631_CR131","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(12)61731-0.","journal-title":"Lancet."},{"key":"1631_CR132","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2147\/VHRM.S36641","volume":"10","author":"A Vuorio","year":"2014","unstructured":"Vuorio A, Tikkanen MJ, Kovanen PT. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vasc Health Risk Manag. 2014;10:263\u201370. https:\/\/doi.org\/10.2147\/VHRM.S36641.","journal-title":"Vasc Health Risk Manag"},{"issue":"9","key":"1631_CR133","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001292.","journal-title":"Circulation."},{"issue":"2","key":"1631_CR134","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.carrev.2014.01.011","volume":"15","author":"EM deGoma","year":"2014","unstructured":"deGoma EM. Lomitapide for the management of homozygous familial hypercholesterolemia. Rev Cardiovasc Med. 2014;15(2):109\u201318.","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"1631_CR135","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/hep4.1042","volume":"1","author":"M Zimmer","year":"2017","unstructured":"Zimmer M, Bista P, Benson EL, Lee DY, Liu F, Picarella D, et al. CAT-2003: a novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun. 2017;1(4):311\u201325. https:\/\/doi.org\/10.1002\/hep4.1042.","journal-title":"Hepatol Commun"},{"key":"1631_CR136","doi-asserted-by":"crossref","unstructured":"Michael Zimmer DP, Feng Liu, Pradeep Bista, Diana Lee, Chi Vu, and Michael Jirousek. CAT-2003 is a Novel Small Molecule That Inhibits Proprotein Convertase Subtilisin\/Kexin Type 9 Production and Lowers Non--High-Density Lipoprotein Cholesterol. Arterioscler Thromb Vasc Biol. 2014:A6.","DOI":"10.1161\/atvb.34.suppl_1.6"},{"key":"1631_CR137","unstructured":"ClinicalTrials.gov Identifier: NCT02098278. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02098278?term=CAT-2003."},{"issue":"151","key":"1631_CR138","first-page":"62","volume":"26","author":"K Hen","year":"2009","unstructured":"Hen K, Bogda\u0144ski P, Pupek-Musialik D. Successful treatment of severe hypertriglyceridemia with plasmapheresis--case report. Pol Merkur Lekarski. 2009;26(151):62\u20134.","journal-title":"Pol Merkur Lekarski"},{"issue":"5","key":"1631_CR139","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00404-013-2786-z","volume":"287","author":"R Basar","year":"2013","unstructured":"Basar R, Uzum AK, Canbaz B, Dogansen SC, Kalayoglu-Besisik S, Altay-Dadin S, et al. Therapeutic apheresis for severe hypertriglyceridemia in pregnancy. Arch Gynecol Obstet. 2013;287(5):839\u201343. https:\/\/doi.org\/10.1007\/s00404-013-2786-z.","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"1631_CR140","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1526-0968.1999.00158.x","volume":"3","author":"A Lennertz","year":"1999","unstructured":"Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher. 1999;3(3):227\u201333. https:\/\/doi.org\/10.1046\/j.1526-0968.1999.00158.x.","journal-title":"Ther Apher"},{"issue":"4","key":"1631_CR141","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4037\/ccn2013346","volume":"33","author":"G Seda","year":"2013","unstructured":"Seda G, Meyer JM, Amundson DE, Daheshia M. Plasmapheresis in the management of severe hypertriglyceridemia. Crit Care Nurse. 2013;33(4):18\u201323; quiz 4. https:\/\/doi.org\/10.4037\/ccn2013346.","journal-title":"Crit Care Nurse"},{"issue":"3","key":"1631_CR142","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3265\/Nefrologia.pre2012.Feb.11394","volume":"32","author":"MJ Izquierdo-Ortiz","year":"2012","unstructured":"Izquierdo-Ortiz MJ, Abaigar-Luquin P. Severe hypertriglyceridaemia. Treatment with plasmapheresis. Nefrologia. 2012;32(3):417\u20138. https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Feb.11394.","journal-title":"Nefrologia."},{"issue":"4","key":"1631_CR143","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jca.20232","volume":"25","author":"H Syed","year":"2010","unstructured":"Syed H, Bilusic M, Rhondla C, Tavaria A. Plasmapheresis in the treatment of hypertriglyceridemia-induced pancreatitis: a community hospital's experience. J Clin Apher. 2010;25(4):229\u201334. https:\/\/doi.org\/10.1002\/jca.20232.","journal-title":"J Clin Apher"},{"issue":"5","key":"1631_CR144","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1567-5688(09)71810-0","volume":"10","author":"N Ewald","year":"2009","unstructured":"Ewald N, Kloer HU. Severe hypertriglyceridemia: an indication for apheresis? Atheroscler Suppl. 2009;10(5):49\u201352. https:\/\/doi.org\/10.1016\/S1567-5688(09)71810-0.","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"1631_CR145","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00000441-200411000-00010","volume":"328","author":"SB Iskandar","year":"2004","unstructured":"Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci. 2004;328(5):290\u20134. https:\/\/doi.org\/10.1097\/00000441-200411000-00010.","journal-title":"Am J Med Sci"},{"key":"1631_CR146","doi-asserted-by":"crossref","unstructured":"Zs\u00edros N, Kov\u00e1cs B, Paragh G, Balla J, Harangi M. Successful plasmapheresis treatment of severe hypertriglyceridemia during late pregnancy. Vessel Plus. 2019;2019.","DOI":"10.20517\/2574-1209.2018.78"},{"issue":"2","key":"1631_CR147","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02785883","volume":"18","author":"JE Dom\u00ednguez-Mu\u00f1oz","year":"1995","unstructured":"Dom\u00ednguez-Mu\u00f1oz JE, J\u00fcnemann F, Malfertheiner P. Hyperlipidemia in acute pancreatitis. Cause or epiphenomenon? Int J Pancreatol. 1995;18(2):101\u20136. https:\/\/doi.org\/10.1007\/BF02785883.","journal-title":"Int J Pancreatol"},{"issue":"15","key":"1631_CR148","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.3748\/wjg.v10.i15.2272","volume":"10","author":"JH Chen","year":"2004","unstructured":"Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10(15):2272\u20134. https:\/\/doi.org\/10.3748\/wjg.v10.i15.2272.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1631_CR149","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00006676-199607000-00013","volume":"13","author":"A Piolot","year":"1996","unstructured":"Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas. 1996;13(1):96\u20139. https:\/\/doi.org\/10.1097\/00006676-199607000-00013.","journal-title":"Pancreas."},{"issue":"6","key":"1631_CR150","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jacl.2014.09.004","volume":"8","author":"M Thuzar","year":"2014","unstructured":"Thuzar M, Shenoy VV, Malabu UH, Schrale R, Sangla KS. Extreme hypertriglyceridemia managed with insulin. J Clin Lipidol. 2014;8(6):630\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2014.09.004.","journal-title":"J Clin Lipidol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-022-01631-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-022-01631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T14:24:27Z","timestamp":1674743067000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-022-01631-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1186\/s12944-022-01631-z","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}